NVO

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.